Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 73 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 6 → 14 locations
  2. Study sites: 5 to 6
    • Eligibility criteria expanded, about 35 words
    • Secondary endpoints: details revised at 3 of 4 entries
  3. Study sites: 4 to 5v71
  4. Study sites: 2 to 4v70
  5. Study sites: 1 to 2v69
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 2 to 1v68
  2. Study sites: 1 to 2v67
  3. Re-verified, no change to tracked fieldsv66
  1. Primary and study completion pushed from Feb 28, 2027 to Dec 31, 2027v65 Show 5 more changesShow less
    • Recruitment opened
    • Start date: May 29, 2026 to Mar 26, 2027
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 56 words
    • Study description expanded, about 42 words
  2. 34 versions Re-verified since Feb 24, 2026, no change to tracked fieldsv31-v64
  3. Start date: Feb 26, 2026 to May 29, 2026v30
  4. 6 versions Re-verified since Feb 12, 2026, no change to tracked fieldsv24-v29
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase Ib trial tests the safety, side effects, and best dose of teclistamab in treating patients with plasmablastic lymphoma that has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen (BCMA), a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving teclistamab may be safe and tolerable in treating patients with recurrent or refractory plasmablastic lymphoma.
Trial Details
NCT Number NCT07332507
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma
Related terms Plasmablastic Lymphoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov